<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37771588</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1230264</StartPage><MedlinePgn>1230264</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1230264</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1230264</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Tsai, Liao, Hsiao, Wu, Lin and Yang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Yi-Giien</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Changhua Christian Children's Hospital, Changhua, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chung Shan Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Pei-Fen</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>School of Medicine, Chung Shan Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Kai-Hung</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Allergy, Immunology and Rheumatology, Changhua Christian Hospital, Changhua, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hung-Ming</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ching-Yuang</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Division of Pediatric Nephrology, Children's Hospital, China Medical University Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kuender D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Mackay Memorial Hospital, New Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="Y">T-Lymphocytes, Regulatory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B regulatory cells</Keyword><Keyword MajorTopicYN="N">interleukin-2</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">regulatory T cells</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>3</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37771588</ArticleId><ArticleId IdType="pmc">PMC10522836</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1230264</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alforaih N, Whittall-Garcia L, Touma Z. A review of lupus nephritis. J Appl Lab Med (2022) 7(6):1450&#x2013;67. doi: 10.1093/jalm/jfac036</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jalm/jfac036</ArticleId><ArticleId IdType="pubmed">35932197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M, Wang C, Shen Q, Ren H, Li L, Li S, et al. . Integrative analysis of omics summary data reveals putative mechanisms linked to different cell populations in systemic lupus erythematosus. Genomics (2022) 114(4):110435. doi: 10.1016/j.ygeno.2022.110435</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2022.110435</ArticleId><ArticleId IdType="pubmed">35878812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford HF, Haljasmagi L, Menon M, McDonnell TCR, Sarekannu K, Vanker M, et al. . Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that norMalize blood IFNalpha and B cell subsets. Cell Rep Med (2023) 4(1):100894. doi:&#xa0;10.1016/j.xcrm.2022.100894</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100894</ArticleId><ArticleId IdType="pmc">PMC9873953</ArticleId><ArticleId IdType="pubmed">36652906</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante B, Mercuri S, Dello Strologo A, Franzin R, Catalano V, Troise D, et al. . Unraveling the link between interferon-alpha and systemic lupus erythematosus: From the molecular mechanisms to target therapies. Int J Mol Sci (2022) 23(24). doi: 10.3390/ijms232415998</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232415998</ArticleId><ArticleId IdType="pmc">PMC9783870</ArticleId><ArticleId IdType="pubmed">36555640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber J, Daridon C, Fleischer SJ, Fleischer V, Hiepe F, Alexander T, et al. . Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation. Arthritis Res Ther (2014) 16(6):477. doi: 10.1186/s13075-014-0477-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-014-0477-1</ArticleId><ArticleId IdType="pmc">PMC4247768</ArticleId><ArticleId IdType="pubmed">25385499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali HN, Alubaidi GT, Gorial FI, Jasim IA. Disturbance in serum levels of IL-17 and TGF-beta1 and in gene expression of ROR-gammat and FOX-P3 is associated with pathogenicity of systematic lupus erythematosus. Prague Med Rep (2022) 123(3):166&#x2013;80. doi: 10.14712/23362936.2022.15</Citation><ArticleIdList><ArticleId IdType="doi">10.14712/23362936.2022.15</ArticleId><ArticleId IdType="pubmed">36107445</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenbrock K, Rauen T. T cell dysregulation in SLE. Clin Immunol (2022) 239:109031. doi: 10.1016/j.clim.2022.109031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109031</ArticleId><ArticleId IdType="pubmed">35526790</ArticleId></ArticleIdList></Reference><Reference><Citation>Skartsis N, Muller YD, Ferreira LMR. Regulatory T cell homeostasis: Requisite signals and implications for clinical development of biologics. Clin Immunol (2023) 246:109201. doi: 10.1016/j.clim.2022.109201</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109201</ArticleId><ArticleId IdType="pubmed">36470337</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HT, Zhang SX, Zhang JQ, Cheng T, Liu Y, Liu HQ, et al. . A decreased number of circulating regulatory T cells is associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. Immun Inflammation Dis (2022) 10(12):e731. doi: 10.1002/iid3.731</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.731</ArticleId><ArticleId IdType="pmc">PMC9639458</ArticleId><ArticleId IdType="pubmed">36444629</ArticleId></ArticleIdList></Reference><Reference><Citation>Giang S, La Cava A. Regulatory T cells in SLE: Biology and use in treatment. Curr Rheumatol Rep (2016) 18(11):67. doi: 10.1007/s11926-016-0616-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-016-0616-6</ArticleId><ArticleId IdType="pubmed">27704250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery HC, Braitch MK, Brown S, Oo YH. Clinical potential of regulatory T cell therapy in liver diseases: An overview and current perspectives. Front Immunol (2016) 7:334. doi: 10.3389/fimmu.2016.00334</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00334</ArticleId><ArticleId IdType="pmc">PMC5012133</ArticleId><ArticleId IdType="pubmed">27656181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao JH, Cheng M, Tang JP, Liu Q, Pan F, Li XP. Foxp3, regulatory T cell, and autoimmune diseases. Inflammation (2017) 40(1):328&#x2013;39. doi: 10.1007/s10753-016-0470-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-016-0470-8</ArticleId><ArticleId IdType="pubmed">27882473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzioannou A, Boumpas A, Papadopoulou M, Papafragkos I, Varveri A, Alissafi T, et al. . Regulatory T cells in autoimmunity and cancer: A duplicitous lifestyle. Front Immunol (2021) 12:731947. doi: 10.3389/fimmu.2021.731947</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.731947</ArticleId><ArticleId IdType="pmc">PMC8446642</ArticleId><ArticleId IdType="pubmed">34539668</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A. Tregs in SLE: an update. Curr Rheumatol Rep (2018) 20(2):6. doi: 10.1007/s11926-018-0714-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-018-0714-8</ArticleId><ArticleId IdType="pubmed">29464438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Zhang X, Su L, Xu L, Zheng Y, Sun J. Fine tuning subsets of CD4(+) T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases. Int Immunopharmacol (2018) 56:269&#x2013;76. doi: 10.1016/j.intimp.2018.01.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.01.042</ArticleId><ArticleId IdType="pubmed">29414661</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, et al. . Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study. Ann Rheum Dis (2022) 81(9):1273&#x2013;80. doi: 10.1136/annrheumdis-2022-222345</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222345</ArticleId><ArticleId IdType="pmc">PMC9380500</ArticleId><ArticleId IdType="pubmed">35609976</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Wang Z, Sun T, Liu S, Ding S, Sun L. Identifying key genes in CD4(+) T cells of systemic lupus erythematosus by integrated bioinformatics analysis. Front Genet (2022) 13:941221. doi: 10.3389/fgene.2022.941221</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.941221</ArticleId><ArticleId IdType="pmc">PMC9420982</ArticleId><ArticleId IdType="pubmed">36046235</ArticleId></ArticleIdList></Reference><Reference><Citation>Corte-Real BF, Arroyo Hornero R, Dyczko A, Hamad I, Kleinewietfeld M. Dissecting the role of CSF2RB expression in human regulatory T cells. Front Immunol (2022) 13:1005965. doi: 10.3389/fimmu.2022.1005965</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1005965</ArticleId><ArticleId IdType="pmc">PMC9755334</ArticleId><ArticleId IdType="pubmed">36532080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding M, Malhotra R, Ottosson T, Lundqvist M, Mebrahtu A, Brengdahl J, et al. . Secretome screening reveals immunomodulating functions of IFNalpha-7, PAP and GDF-7 on regulatory T-cells. Sci Rep (2021) 11(1):16767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373891</ArticleId><ArticleId IdType="pubmed">34408239</ArticleId></ArticleIdList></Reference><Reference><Citation>Roach T, Morel L. Genetic variations controlling regulatory T cell development and activity in mouse models of lupus-like autoimmunity. Front Immunol (2022) 13:887489. doi: 10.3389/fimmu.2022.887489</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.887489</ArticleId><ArticleId IdType="pmc">PMC9178176</ArticleId><ArticleId IdType="pubmed">35693798</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinecker C, Goschl L, Bonelli M. Treg cells in health and autoimmune diseases: New insights from single cell analysis. J Autoimmun (2020) 110:102376. doi: 10.1016/j.jaut.2019.102376</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102376</ArticleId><ArticleId IdType="pubmed">31862128</ArticleId></ArticleIdList></Reference><Reference><Citation>Doglio M, Alexander T, Del Papa N, Snowden JA, Greco R, Autoimmune Diseases Working Party of the European Society for B et al. . New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies. J Allergy Clin Immunol (2022) 150(6):1289&#x2013;301. doi: 10.1016/j.jaci.2022.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.08.003</ArticleId><ArticleId IdType="pubmed">36137815</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhang Q, Luo S, Zhang H, Lu Q, Long H. Advances in therapeutic targets-related study on systemic lupus erythematosus. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2021) 46(11):1267&#x2013;75. doi:&#xa0;10.11817/j.issn.1672-7347.2021.200056</Citation><ArticleIdList><ArticleId IdType="doi">10.11817/j.issn.1672-7347.2021.200056</ArticleId><ArticleId IdType="pubmed">34911862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizui M, Tsokos GC. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front Immunol (2018) 9:786. doi: 10.3389/fimmu.2018.00786</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00786</ArticleId><ArticleId IdType="pmc">PMC5932391</ArticleId><ArticleId IdType="pubmed">29755456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghali JR, Wang YM, Holdsworth SR, Kitching AR. Regulatory T cells in immune-mediated renal disease. Nephrol (Carlton) (2016) 21(2):86&#x2013;96. doi: 10.1111/nep.12574</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.12574</ArticleId><ArticleId IdType="pubmed">26206106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko M, Jackson SW. Recent advances in immunotherapies for lupus nephritis. Pediatr Nephrol (2023) 38(4):1001&#x2013;12. doi: 10.1007/s00467-022-05670-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-022-05670-7</ArticleId><ArticleId IdType="pmc">PMC10219838</ArticleId><ArticleId IdType="pubmed">35778517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghobadinezhad F, Ebrahimi N, Mozaffari F, Moradi N, Beiranvand S, Pournazari M, et al. . The emerging role of regulatory cell-based therapy in autoimmune disease. Front Immunol (2022) 13:1075813. doi: 10.3389/fimmu.2022.1075813</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1075813</ArticleId><ArticleId IdType="pmc">PMC9795194</ArticleId><ArticleId IdType="pubmed">36591309</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RP, Bischoff DS, Hahn BH. CD8(+) T regulatory cells in lupus. Rheumatol Immunol Res (2021) 2(3):147&#x2013;56. doi: 10.2478/rir-2021-0021</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rir-2021-0021</ArticleId><ArticleId IdType="pmc">PMC9242525</ArticleId><ArticleId IdType="pubmed">35880241</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Huang Y, Ming B, Wu X, Chen Y, Dong L. Regulatory T-cell levels in systemic lupus erythematosus patients: a meta-analysis. Lupus (2019) 28(4):445&#x2013;54. doi: 10.1177/0961203319828530</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319828530</ArticleId><ArticleId IdType="pubmed">30744525</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Deng C, Yang H, Wang G. The regulatory T cell in active systemic lupus erythematosus patients: A systemic review and meta-analysis. Front Immunol (2019) 10:159. doi: 10.3389/fimmu.2019.00159</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00159</ArticleId><ArticleId IdType="pmc">PMC6387904</ArticleId><ArticleId IdType="pubmed">30833946</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SX, Ma XW, Li YF, Lai NL, Huang ZH, Fan K, et al. . The proportion of regulatory T cells in patients with systemic lupus erythematosus: A meta-analysis. J Immunol Res 2018 (2018) p:7103219. doi: 10.1155/2018/7103219</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7103219</ArticleId><ArticleId IdType="pmc">PMC6140280</ArticleId><ArticleId IdType="pubmed">30255107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu J, Zheng N, Mao C, Liu S, Zhang H, Sun L. UC-BSCs Exosomes Regulate Th17/Treg Balance in Patients with Systemic Lupus Erythematosus via miR-19b/KLF13. Cells (2022) 11(24). doi: 10.3390/cells11244123</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11244123</ArticleId><ArticleId IdType="pmc">PMC9777319</ArticleId><ArticleId IdType="pubmed">36552891</ArticleId></ArticleIdList></Reference><Reference><Citation>Divekar AA, Dubey S, Gangalum PR, Singh RR. Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol (2011) 186(2):924&#x2013;30. doi: 10.4049/jimmunol.1002218</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002218</ArticleId><ArticleId IdType="pmc">PMC3038632</ArticleId><ArticleId IdType="pubmed">21149603</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 177(3):1451&#x2013;9. doi: 10.4049/jimmunol.177.3.1451</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.3.1451</ArticleId><ArticleId IdType="pubmed">16849451</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, Weigert O, et al. . Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U.S.A. (2010) 107(1):204&#x2013;9. doi: 10.1073/pnas.0903158107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903158107</ArticleId><ArticleId IdType="pmc">PMC2806746</ArticleId><ArticleId IdType="pubmed">20018660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurata I, Mikami N, Ohyama A, Osada A, Kondo Y, Tsuboi H, et al. . Impaired function of PD-1(+) follicular regulatory T cells in systemic lupus erythematosus. Clin Exp Immunol (2021) 206(1):28&#x2013;35. doi: 10.1111/cei.13643</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13643</ArticleId><ArticleId IdType="pmc">PMC8446397</ArticleId><ArticleId IdType="pubmed">34240405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao H, Nakayamada S, Yamagata K, Ohkubo N, Iwata S, Inoue Y, et al. . Conversion of T follicular helper cells to T follicular regulatory cells by interleukin-2 through transcriptional regulation in systemic lupus erythematosus. Arthritis Rheumatol (2021) 73(1):132&#x2013;42. doi: 10.1002/art.41457</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41457</ArticleId><ArticleId IdType="pubmed">32720470</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Wang S, Zhou M, Huang Y, Fu R, Guo C, et al. . The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin Immunol (2017) 183:46&#x2013;53. doi: 10.1016/j.clim.2017.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.07.004</ArticleId><ArticleId IdType="pmc">PMC5673570</ArticleId><ArticleId IdType="pubmed">28709914</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Yang X, Yang J, Li M. Baicalin ameliorates lupus autoimmunity by inhibiting differentiation of Tfh cells and inducing expansion of Tfr cells. Cell Death Dis (2019) 10(2):140. doi: 10.1038/s41419-019-1315-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1315-9</ArticleId><ArticleId IdType="pmc">PMC6374440</ArticleId><ArticleId IdType="pubmed">30760702</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai YG, Lee CY, Lin TY, Lin CY. CD8(+) Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria. PloS One (2014) 9(1):e81344. doi: 10.1371/journal.pone.0081344</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0081344</ArticleId><ArticleId IdType="pmc">PMC3903465</ArticleId><ArticleId IdType="pubmed">24475019</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Bertucci AM, Ramsey-Goldman R, Harsha-Strong ER, Burt RK, Datta SK. Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity. Clin Immunol (2013) 149(3):365&#x2013;78. doi: 10.1016/j.clim.2013.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2013.08.008</ArticleId><ArticleId IdType="pmc">PMC3849335</ArticleId><ArticleId IdType="pubmed">24211843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol (2009) 183(10):6346&#x2013;58. doi: 10.4049/jimmunol.0901773</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901773</ArticleId><ArticleId IdType="pmc">PMC2784684</ArticleId><ArticleId IdType="pubmed">19841178</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Ouyang X, Xu Z, Chen J, Huang Q, Liu Y, et al. . CD8+CD103+ iTregs inhibit chronic graft-versus-host disease with lupus nephritis by the increased expression of CD39. Mol Ther (2019) 27(11):1963&#x2013;73. doi: 10.1016/j.ymthe.2019.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.07.014</ArticleId><ArticleId IdType="pmc">PMC6838901</ArticleId><ArticleId IdType="pubmed">31402273</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan GC, Singh RR. Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med (2002) 196(6):731&#x2013;41. doi: 10.1084/jem.20020223</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20020223</ArticleId><ArticleId IdType="pmc">PMC2194049</ArticleId><ArticleId IdType="pubmed">12235207</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RP, La Cava A, Hahn BH. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol (2008) 180(4):2069&#x2013;80. doi: 10.4049/jimmunol.180.4.2069</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.4.2069</ArticleId><ArticleId IdType="pubmed">18250412</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RP, La Cava A, Wong M, Ebling F, Hahn BH. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol (2007) 178(12):7649&#x2013;57. doi: 10.4049/jimmunol.178.12.7649</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.12.7649</ArticleId><ArticleId IdType="pubmed">17548601</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H, Tang Z, Xu Y, Shi Z, Guo Z, Liu X, et al. . CD19(+)CD24(high)CD27(+) B cell and interleukin 35 as potential biomarkers of disease activity in systemic lupus erythematosus patients. Adv Rheumatol (2022) 62(1):48.</Citation><ArticleIdList><ArticleId IdType="pubmed">36494762</ArticleId></ArticleIdList></Reference><Reference><Citation>Girimaji N, Kaundal U, Rathi M, Sharma A, Nada R, Ramachandran R, et al. . Regulatory B and T cells and their association with clinical response in new-onset lupus nephritis patients. Kidney Int Rep (2020) 5(7):1081&#x2013;6. doi: 10.1016/j.ekir.2020.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.04.019</ArticleId><ArticleId IdType="pmc">PMC7335952</ArticleId><ArticleId IdType="pubmed">32647769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Z, Jiang Y, Sun D, Zhong W, Zhao L, Jiang Z. The plasma interleukin (IL)-35 level and frequency of circulating IL-35(+) regulatory B cells are decreased in a cohort of Chinese patients with new-onset systemic lupus erythematosus. Sci Rep (2019) 9(1):13210. doi: 10.1038/s41598-019-49748-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-49748-z</ArticleId><ArticleId IdType="pmc">PMC6744462</ArticleId><ArticleId IdType="pubmed">31519970</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon M, Blair PA, Isenberg DA, Mauri C. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity (2016) 44(3):683&#x2013;97. doi: 10.1016/j.immuni.2016.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.02.012</ArticleId><ArticleId IdType="pmc">PMC4803914</ArticleId><ArticleId IdType="pubmed">26968426</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinemann K, Wilde B, Hoerning A, Tebbe B, Kribben A, Witzke O, et al. . Decreased IL-10(+) regulatory B cells (Bregs) in lupus nephritis patients. Scand J Rheumatol (2016) 45(4):312&#x2013;6. doi: 10.3109/03009742.2015.1126346</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2015.1126346</ArticleId><ArticleId IdType="pubmed">26948375</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L, Weiqian C, Lihuan Y. Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in naive systemic lupus erythematosus. Int J Rheum Dis (2013) 16(6):698&#x2013;708. doi: 10.1111/1756-185X.12229</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12229</ArticleId><ArticleId IdType="pubmed">24286662</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. . CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 32(1):129&#x2013;40. doi: 10.1016/j.immuni.2009.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.11.009</ArticleId><ArticleId IdType="pubmed">20079667</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yang J, Chu Y, Wang J, Guan M, Zhu X, et al. . T follicular helper cells mediate expansion of regulatory B cells via IL-21 in Lupus-prone MRL/lpr mice. PloS One (2013) 8(4):e62855. doi:&#xa0;10.1371/journal.pone.0062855</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062855</ArticleId><ArticleId IdType="pmc">PMC3634758</ArticleId><ArticleId IdType="pubmed">23638156</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Lee SH, Seo HB, Ryu JG, Jung K, Choi JW, et al. . Inhibition of IL-17 ameliorates systemic lupus erythematosus in Roquin(san/san) mice through regulating the balance of TFH cells, GC B cells, Treg and Breg. Sci Rep (2019) 9(1):5227. doi:&#xa0;10.1038/s41598-019-41534-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41534-1</ArticleId><ArticleId IdType="pmc">PMC6435653</ArticleId><ArticleId IdType="pubmed">30914691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Q, Edwards MR, Swartwout BK, Cabana Puig X, Mao J, Zhu J, et al. . Gut microbiota and bacterial DNA suppress autoimmunity by stimulating regulatory B cells in a murine model of lupus. Front Immunol (2020) 11:593353. doi: 10.3389/fimmu.2020.593353</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.593353</ArticleId><ArticleId IdType="pmc">PMC7683516</ArticleId><ArticleId IdType="pubmed">33240280</ArticleId></ArticleIdList></Reference><Reference><Citation>Facciotti F, Gagliani N, Haringer B, Alfen JS, Penatti A, Maglie S, et al. . IL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus. J Allergy Clin Immunol (2016) 137(1):318&#x2013;321 e5. doi: 10.1016/j.jaci.2015.06.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.06.044</ArticleId><ArticleId IdType="pubmed">26318071</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai YG, Chien JW, Chiu YM, Su TC, Chiu PF, Hsiao KH, et al. . Lupus nephritis with corticosteroid responsiveness: molecular changes of CD46-mediated type 1 regulatory T cells. Pediatr Res (2022) 92(4):1099&#x2013;107. doi: 10.1038/s41390-021-01882-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-021-01882-z</ArticleId><ArticleId IdType="pubmed">34952938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellinghaus U, Cortini A, Pinder CL, Le Friec G, Kemper C, Vyse TJ. Dysregulated CD46 shedding interferes with Th1-contraction in systemic lupus erythematosus. Eur J Immunol (2017) 47(7):1200&#x2013;10. doi: 10.1002/eji.201646822</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201646822</ArticleId><ArticleId IdType="pmc">PMC5507296</ArticleId><ArticleId IdType="pubmed">28444759</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Buanec H, Gougeon ML, Mathian A, Lebon P, Dupont JM, Peltre G, et al. . IFN-alpha and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc Natl Acad Sci U.S.A. (2011) 108(47):18995&#x2013;9000. doi: 10.1073/pnas.1113301108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1113301108</ArticleId><ArticleId IdType="pmc">PMC3223453</ArticleId><ArticleId IdType="pubmed">22065791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR, Yoo WH. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatol (Oxford) (2008) 47(6):789&#x2013;94. doi: 10.1093/rheumatology/ken108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ken108</ArticleId><ArticleId IdType="pubmed">18388146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellor-Pita S, Citores MJ, Castejon R, Tutor-Ureta P, Yebra-Bango M, Andreu JL, et al. . Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis (2006) 65(4):553&#x2013;4. doi: 10.1136/ard.2005.044974</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.044974</ArticleId><ArticleId IdType="pmc">PMC1798083</ArticleId><ArticleId IdType="pubmed">16531555</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Luo L, Wu Y, Song Z, Ni B, Hao F, et al. . Elevated apoptosis and abnormal apoptosis signaling of regulatory T cells in patients with systemic lupus erythematosus. Lupus (2022) 31(12):1441&#x2013;55. doi: 10.1177/09612033221119455</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221119455</ArticleId><ArticleId IdType="pubmed">35950636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu D, Senouthai S, Wang J, You Y. Vasoactive intestinal peptide ameliorates renal injury in a pristane-induced lupus mouse model by modulating Th17/Treg balance. BMC Nephrol (2019) 20(1):350. doi: 10.1186/s12882-019-1548-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-019-1548-y</ArticleId><ArticleId IdType="pmc">PMC6728947</ArticleId><ArticleId IdType="pubmed">31488076</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao M, Xiao X, Tian J, Zhufeng Y, Feng R, Zhang R, et al. . Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res Ther (2021) 23(1):167. doi: 10.1186/s13075-021-02535-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02535-6</ArticleId><ArticleId IdType="pmc">PMC8194162</ArticleId><ArticleId IdType="pubmed">34116715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X, Zhang J, Zhou X. Ex-TFRs: A missing piece of the SLE puzzle? Front Immunol (2021) 12:662305. doi: 10.3389/fimmu.2021.662305</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.662305</ArticleId><ArticleId IdType="pmc">PMC8062926</ArticleId><ArticleId IdType="pubmed">33897710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballesteros-Tato A, Papillion A. Mechanisms of action of low-dose IL-2 restoration therapies in SLE. Curr Opin Immunol (2019) 61:39&#x2013;45. doi: 10.1016/j.coi.2019.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2019.07.003</ArticleId><ArticleId IdType="pubmed">31450016</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol (2007) 178(1):280&#x2013;90. doi: 10.4049/jimmunol.178.1.280</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.1.280</ArticleId><ArticleId IdType="pubmed">17182565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao H, Nakayamada S, Ohkubo N, Yamagata K, Zhang M, Shan Y, et al. . Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. Arthritis Res Ther (2021) 23(1):302. doi: 10.1186/s13075-021-02682-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02682-w</ArticleId><ArticleId IdType="pmc">PMC8665514</ArticleId><ArticleId IdType="pubmed">34895341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W, Sunahori K, Zhao J, Deng Y, Kaufman KM, Kelly JA, et al. . Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum (2011) 63(9):2755&#x2013;63. doi: 10.1002/art.30452</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30452</ArticleId><ArticleId IdType="pmc">PMC3163110</ArticleId><ArticleId IdType="pubmed">21590681</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey LA. Human regulatory CD8(+) T cells. Nat Immunol (2022) 23(5):645. doi: 10.1038/s41590-022-01206-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01206-1</ArticleId><ArticleId IdType="pubmed">35487989</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai YG, Yang KD, Wen YS, Hung CH, Chien JW, Lin CY. Allergen-specific immunotherapy enhances CD8(+) CD25(+) CD137(+) regulatory T cells and decreases nasal nitric oxide. Pediatr Allergy Immunol (2019) 30(5):531&#x2013;9. doi: 10.1111/pai.13061</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.13061</ArticleId><ArticleId IdType="pubmed">30968455</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RP, Hahn BH, Bischoff DS. Cellular and molecular phenotypes of pConsensus peptide (pCons) induced CD8(+) and CD4(+) regulatory T cells in lupus. Front Immunol (2021) 12:718359. doi: 10.3389/fimmu.2021.718359</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.718359</ArticleId><ArticleId IdType="pmc">PMC8640085</ArticleId><ArticleId IdType="pubmed">34867947</ArticleId></ArticleIdList></Reference><Reference><Citation>Liston A, Aloulou M. A fresh look at a neglected regulatory lineage: CD8(+)Foxp3(+) Regulatory T cells . Immunol Lett (2022) 247:22&#x2013;6. doi: 10.1016/j.imlet.2022.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2022.05.004</ArticleId><ArticleId IdType="pubmed">35609830</ArticleId></ArticleIdList></Reference><Reference><Citation>Levescot A, Cerf-Bensussan N. Regulatory CD8(+) T cells suppress disease. Science (2022) 376(6590):243&#x2013;4. doi: 10.1126/science.abp8243</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abp8243</ArticleId><ArticleId IdType="pubmed">35420956</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 189(12):5590&#x2013;601. doi: 10.4049/jimmunol.1201744</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1201744</ArticleId><ArticleId IdType="pmc">PMC3735346</ArticleId><ArticleId IdType="pubmed">23152566</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz DA, Bickerton S, La Cava A. Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases. Front Immunol (2021) 12:681062. doi: 10.3389/fimmu.2021.681062</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.681062</ArticleId><ArticleId IdType="pmc">PMC8239238</ArticleId><ArticleId IdType="pubmed">34211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Liu Y, Li Y, Gu J, Liu J, Tang J, et al. . Differential role of all-trans retinoic acid in promoting the development of CD4+ and CD8+ regulatory T cells. J Leukoc Biol (2014) 95(2):275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896662</ArticleId><ArticleId IdType="pubmed">24082012</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun W, Tian J, Zhang Y. Transplantation of mesenchymal stem cells ameliorates systemic lupus erythematosus and upregulates B10 cells through TGF-beta1. Stem Cell Res Ther (2021) 12(1):512. doi:&#xa0;10.1186/s13287-021-02586-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-021-02586-1</ArticleId><ArticleId IdType="pmc">PMC8466915</ArticleId><ArticleId IdType="pubmed">34563233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Su Z, Barnie PA. The role of B regulatory (B10) cells in inflammatory disorders and their potential as therapeutic targets. Int Immunopharmacol (2020) 78:106111. doi: 10.1016/j.intimp.2019.106111</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.106111</ArticleId><ArticleId IdType="pubmed">31881524</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri C. Novel frontiers in regulatory B cells. Immunol Rev (2021) 299(1):5&#x2013;9. doi: 10.1111/imr.12964</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12964</ArticleId><ArticleId IdType="pubmed">33686653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai M, Xu L, Zhu H, Xue J, Liu T, Sun F, et al. . Impaired granzyme B-producing regulatory B cells in systemic lupus erythematosus. Mol Immunol (2021) 140:217&#x2013;24. doi: 10.1016/j.molimm.2021.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2021.09.012</ArticleId><ArticleId IdType="pubmed">34749262</ArticleId></ArticleIdList></Reference><Reference><Citation>Cencioni MT, Ali R, Nicholas R, Muraro PA. Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS. Mult Scler (2021) 27(8):1187&#x2013;97. doi: 10.1177/1352458520951536</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520951536</ArticleId><ArticleId IdType="pubmed">32924828</ArticleId></ArticleIdList></Reference><Reference><Citation>Szelinski F, Lino AC, Dorner T. B cells in systemic lupus erythematosus. Curr Opin Rheumatol (2022) 34(2):125&#x2013;32. doi: 10.1097/BOR.0000000000000865</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000865</ArticleId><ArticleId IdType="pubmed">34939607</ArticleId></ArticleIdList></Reference><Reference><Citation>Oleinika K, Mauri C, Salama AD. Effector and regulatory B cells in immune-mediated kidney disease. Nat Rev Nephrol (2019) 15(1):11&#x2013;26. doi: 10.1038/s41581-018-0074-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-018-0074-7</ArticleId><ArticleId IdType="pubmed">30443016</ArticleId></ArticleIdList></Reference><Reference><Citation>Achour A, Simon Q, Mohr A, Seite JF, Youinou P, Bendaoud B, et al. . Human regulatory B cells control the T(FH) cell response. J Allergy Clin Immunol (2017) 140(1):215&#x2013;22. doi: 10.1016/j.jaci.2016.09.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.09.042</ArticleId><ArticleId IdType="pubmed">27865860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Liao Y, Liang J, Chen X, Li S, Liu W, et al. . Immunomodulation of human CD19(+)CD25(high) regulatory B cells via Th17/Foxp3 regulatory T cells and Th1/Th2 cytokines. Hum Immunol (2019) 80(10):863&#x2013;70. doi: 10.1016/j.humimm.2019.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2019.05.011</ArticleId><ArticleId IdType="pubmed">31262519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding T, Su R, Wu R, Xue H, Wang Y, Su R, et al. . Frontiers of autoantibodies in autoimmune disorders: Crosstalk between tfh/tfr and regulatory B cells. Front Immunol (2021) 12:641013. doi: 10.3389/fimmu.2021.641013</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.641013</ArticleId><ArticleId IdType="pmc">PMC8033031</ArticleId><ArticleId IdType="pubmed">33841422</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun (2015) 6:5997. doi: 10.1038/ncomms6997</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6997</ArticleId><ArticleId IdType="pubmed">25609381</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Sollner S, Akdis DG, et al. . IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol (2013) 131(4):1204&#x2013;12. doi: 10.1016/j.jaci.2013.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2013.01.014</ArticleId><ArticleId IdType="pubmed">23453135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayitoglu EC, Freeborn RA, Roncarolo MG. The yin and yang of type 1 regulatory T cells: From discovery to clinical application. Front Immunol (2021) 12:693105. doi: 10.3389/fimmu.2021.693105</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.693105</ArticleId><ArticleId IdType="pmc">PMC8222711</ArticleId><ArticleId IdType="pubmed">34177953</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborn RA, Strubbe S, Roncarolo MG. Type 1 regulatory T cell-mediated tolerance in health and disease. Front Immunol (2022) 13:1032575. doi: 10.3389/fimmu.2022.1032575</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1032575</ArticleId><ArticleId IdType="pmc">PMC9650496</ArticleId><ArticleId IdType="pubmed">36389662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, et al. . Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol (2010) 11(9):846&#x2013;53. doi: 10.1038/ni.1915</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1915</ArticleId><ArticleId IdType="pmc">PMC2929008</ArticleId><ArticleId IdType="pubmed">20676092</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmetterer KG, Neunkirchner A, Wojta-Stremayr D, Leitner J, Steinberger P, Pickl WF. STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4+ T cells. FASEB J (2015) 29(3):759&#x2013;71. doi: 10.1096/fj.14-257584</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-257584</ArticleId><ArticleId IdType="pmc">PMC4422363</ArticleId><ArticleId IdType="pubmed">25398767</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. . Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 116(6):935&#x2013;44. doi: 10.1182/blood-2009-07-234872</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-07-234872</ArticleId><ArticleId IdType="pubmed">20448110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardone J, Le Friec G, Vantourout P, Roberts A, Fuchs A, Jackson I, et al. . Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 11(9):862&#x2013;71. doi: 10.1038/ni.1917</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1917</ArticleId><ArticleId IdType="pmc">PMC4011020</ArticleId><ArticleId IdType="pubmed">20694009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 421(6921):388&#x2013;92. doi: 10.1038/nature01315</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01315</ArticleId><ArticleId IdType="pubmed">12540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Alegretti AP, Schneider L, Piccoli AK, Xavier RM. The role of complement regulatory proteins in peripheral blood cells of patients with systemic lupus erythematosus: review. Cell Immunol (2012) 277(1-2):1&#x2013;7. doi: 10.1016/j.cellimm.2012.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2012.06.008</ArticleId><ArticleId IdType="pubmed">22795896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Sun J, Yuan Y, Ji D, Sun Y, Liu Y, et al. . Proximity-enabled covalent binding of IL-2 to IL-2Ralpha selectively activates regulatory T cells and suppresses autoimmunity. Signal Transduct Target Ther (2023) 8(1):28. doi:&#xa0;10.1038/s41392-022-01208-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01208-3</ArticleId><ArticleId IdType="pmc">PMC9871032</ArticleId><ArticleId IdType="pubmed">36690610</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu H, Yan H, Xiong J. Research advances on targeted-Treg therapies on immune-mediated kidney diseases. Autoimmun Rev (2023) 22(2):103257. doi: 10.1016/j.autrev.2022.103257</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103257</ArticleId><ArticleId IdType="pubmed">36563769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JL, Lyu TB, Chen ZL, Lian CF, Liu SY, Shao TH, et al. . Methylprednisolone pulse therapy promotes the differentiation of regulatory T cells by inducing the apoptosis of CD4(+) T cells in patients with systemic lupus erythematosus. Clin Immunol (2022) 241:109079. doi: 10.1016/j.clim.2022.109079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109079</ArticleId><ArticleId IdType="pubmed">35842211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Wang S, Wang S, Xie J, Cui D. mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus. Clin Immunol (2022) 245:109153. doi: 10.1016/j.clim.2022.109153</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109153</ArticleId><ArticleId IdType="pubmed">36265758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Zhao C, Zhang B, Wang X, Wang Y, An J, et al. . Restoring T-helper 17 cell/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus. Lupus (2019) 28(12):1397&#x2013;406. doi: 10.1177/0961203319877239</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319877239</ArticleId><ArticleId IdType="pubmed">31551029</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SK. Harnessing tolerogenic histone peptide epitopes from nucleosomes for selective down-regulation of pathogenic autoimmune response in lupus (Past, present, and future). Front Immunol (2021) 12:629807. doi: 10.3389/fimmu.2021.629807</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.629807</ArticleId><ArticleId IdType="pmc">PMC8080879</ArticleId><ArticleId IdType="pubmed">33936042</ArticleId></ArticleIdList></Reference><Reference><Citation>Giang S, Horwitz DA, Bickerton S, La Cava A. Nanoparticles engineered as artificial antigen-presenting cells induce human CD4(+) and CD8(+) tregs that are functional in humanized mice. Front Immunol (2021) 12:628059. doi: 10.3389/fimmu.2021.628059</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.628059</ArticleId><ArticleId IdType="pmc">PMC8189151</ArticleId><ArticleId IdType="pubmed">34122401</ArticleId></ArticleIdList></Reference><Reference><Citation>Papillion A, Ballesteros-Tato A. The potential of harnessing IL-2-mediated immunosuppression to prevent pathogenic B cell responses. Front Immunol (2021) 12:667342. doi: 10.3389/fimmu.2021.667342</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.667342</ArticleId><ArticleId IdType="pmc">PMC8112607</ArticleId><ArticleId IdType="pubmed">33986755</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, et al. . Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity (2007) 26(3):371&#x2013;81. doi: 10.1016/j.immuni.2007.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.02.009</ArticleId><ArticleId IdType="pubmed">17363300</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson S, Thomas R. Potential for antigen-specific tolerizing immunotherapy in systematic lupus erythematosus. Front Immunol (2021) 12:654701. doi: 10.3389/fimmu.2021.654701</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.654701</ArticleId><ArticleId IdType="pmc">PMC8322693</ArticleId><ArticleId IdType="pubmed">34335564</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Pan W, Hisada R, Boulougoura A, Yoshida N, Vukelic M, et al. . Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity. Sci Adv (2022) 8(48):eadc9657. doi: 10.1126/sciadv.adc9657</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adc9657</ArticleId><ArticleId IdType="pmc">PMC9710877</ArticleId><ArticleId IdType="pubmed">36449620</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Boulougoura A, Endo Y, Tsokos GC. AbnorMalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. J Autoimmun (2022) 132:102870. doi: 10.1016/j.jaut.2022.102870</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102870</ArticleId><ArticleId IdType="pubmed">35872102</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatadri R, Sabapathy V, Dogan M, Sharma R. Targeting regulatory T cells for therapy of lupus nephritis. Front Pharmacol (2021) 12:806612. doi: 10.3389/fphar.2021.806612</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.806612</ArticleId><ArticleId IdType="pmc">PMC8775001</ArticleId><ArticleId IdType="pubmed">35069220</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloder J, Shahneh F, Schneider FJ, Wieschendorf B. Boosting regulatory T cell function for the treatment of autoimmune diseases - That's only half the battle! Front Immunol (2022) 13:973813. doi: 10.3389/fimmu.2022.973813</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.973813</ArticleId><ArticleId IdType="pmc">PMC9400058</ArticleId><ArticleId IdType="pubmed">36032121</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendeeran A, Tenbrock K. Regulatory T cell function in autoimmune disease. J Transl Autoimmun (2021) 4:100130. doi: 10.1016/j.jtauto.2021.100130</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100130</ArticleId><ArticleId IdType="pmc">PMC8716637</ArticleId><ArticleId IdType="pubmed">35005594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl K, Tenbrock K. [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance]. Z Rheumatol (2016) 75(3):253&#x2013;64. doi:&#xa0;10.1007/s00393-016-0060-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-016-0060-z</ArticleId><ArticleId IdType="pubmed">26975190</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathman CG, Yip L, Gomez-Martin D, Yu M, Seroogy CM, Hurt CR, et al. . How GRAIL controls Treg function to maintain self-tolerance. Front Immunol (2022) 13:1046631. doi: 10.3389/fimmu.2022.1046631</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1046631</ArticleId><ArticleId IdType="pmc">PMC9773990</ArticleId><ArticleId IdType="pubmed">36569931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Perl A. Double-Edged Sword: Interleukin-2 Promotes T Regulatory Cell Differentiation but Also Expands Interleukin-13- and Interferon-gamma-Producing CD8(+) T Cells via STAT6-GATA-3 Axis in Systemic Lupus Erythematosus. Front Immunol (2021) 12:635531. doi: 10.3389/fimmu.2021.635531</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.635531</ArticleId><ArticleId IdType="pmc">PMC7982885</ArticleId><ArticleId IdType="pubmed">33763079</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang K, He J, Wei Y, Zeng Q, Gong D, Qin J, et al. . Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus. Clin Transl Immunol (2021) 10(6):e1293. doi: 10.1002/cti2.1293</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1293</ArticleId><ArticleId IdType="pmc">PMC8169300</ArticleId><ArticleId IdType="pubmed">34094549</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. . Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2020) 79(1):141&#x2013;9. doi: 10.1136/annrheumdis-2019-215396</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215396</ArticleId><ArticleId IdType="pmc">PMC6937406</ArticleId><ArticleId IdType="pubmed">31537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, et al. . Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis (2015) 74(4):791&#x2013;2. doi: 10.1136/annrheumdis-2014-206506</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206506</ArticleId><ArticleId IdType="pubmed">25609413</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, et al. . Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis (2022) 81(12):1685&#x2013;94. doi: 10.1136/ard-2022-222501</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222501</ArticleId><ArticleId IdType="pubmed">35973803</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanton C, Furie R, Chindalore V, Levin R, Diab I, Dixit N, et al. . Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J Transl Autoimmun (2022) 5:100152. doi: 10.1016/j.jtauto.2022.100152</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2022.100152</ArticleId><ArticleId IdType="pmc">PMC9062472</ArticleId><ArticleId IdType="pubmed">35517914</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao M, He J, Zhang R, Zhang X, Yang Y, Li C, et al. . Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus. J Interferon Cytokine Res (2019) 39(2):117&#x2013;24. doi: 10.1089/jir.2018.0016</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2018.0016</ArticleId><ArticleId IdType="pubmed">30721117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Chu Y, Liang Z, Zhang B, Wang X, Jing X, et al. . Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients. BMC Immunol (2019) 20(1):32. doi: 10.1186/s12865-019-0305-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-019-0305-0</ArticleId><ArticleId IdType="pmc">PMC6727508</ArticleId><ArticleId IdType="pubmed">31484501</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Riemekasten G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol (2019) 31(2):208&#x2013;12. doi: 10.1097/BOR.0000000000000575</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000575</ArticleId><ArticleId IdType="pubmed">30562181</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarzadeh R, Riemekasten G, Humrich JY. Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosu. Curr Opin Rheumatol (2023) 35(2):98&#x2013;106. doi: 10.1097/BOR.0000000000000924</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000924</ArticleId><ArticleId IdType="pubmed">36563007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>